Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use...

Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO Company Appoints Biotech Industry Leaders Ronen Twito, CPA...

No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up...

AstroRx® demonstrated to be safe and well tolerated in the higher treatment dose Clinically meaningful decline in disease progression...

No treatment-related serious adverse events nor dose-limiting toxicities were reported A statistically significant decline in disease...

The patients in this Cohort were treated with a single dose of 250x106 cells of AstroRx® The clinical trial continues as planned. Cohort...

Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time Unique technology...

Following Recent Positive Interim Results The Company intends to assess the safety and efficacy of a repeated administration of the low...

Kadimastem to Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in...

Disease progression was reduced in the first 3 months post-treatment period compared to the 3 months pre-treatment period, this...

NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef...

Ness Ziona, Israel, April 18th 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval from the MOH of...

The Current CFO has accepted a position as the Director of the Budget Division of the Jewish Agency for Israel Ness Ziona, Israel, 3...

Ness Ziona, Israel, 24 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of cell...

Ness Ziona, Israel, 17 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announces it has received approval for its...

Ness Ziona, Israel, November 27, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) received an announcement from the TASE, that...

Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise...

Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the approval by the European Union...

The FDA grants orphan drug status to incentivize the development of one of a kind drugs and other medical treatments. This status grants...

Ness Ziona, Israel, October 9, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces progress in the Phase 1 / 2a...